enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Comparison of bicalutamide with other antiandrogens

   en.wikipedia.org/wiki/Comparison_of_bicalutamide...

   Relative to steroidal antiandrogens like cyproterone acetate and spironolactone, bicalutamide has better selectivity in its action, superior efficacy as an antagonist of the androgen receptor, and better tolerability. Bicalutamide also shows a better safety profile than cyproterone acetate. When used as a high-dosage monotherapy, bicalutamide ...

3. Management of prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Management_of_prostate_cancer

   Palliative care for advanced-stage prostate cancer focuses on extending life and relieving the symptoms of metastatic disease. As noted above, abiraterone is showing some promise in treating advanced-stage prostate cancer. It causes a dramatic reduction in PSA levels and tumor sizes in aggressive advanced-stage prostate cancer for 70% of patients.

4. Prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Prostate_cancer

   Prostate cancer is the most diagnosed cancer in men in over half of the world's countries, and the leading cause of cancer death in men in around a quarter of countries. [90] Prostate cancer is rare in those under 40 years old, [91] and most cases occur in those over 60 years, [2] with the average person diagnosed at 67. [92]

5. Androgen deprivation therapy - Wikipedia

   en.wikipedia.org/wiki/Androgen_deprivation_therapy

   Androgen deprivation therapy. Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones ...

6. Medical uses of bicalutamide - Wikipedia

   en.wikipedia.org/wiki/Medical_uses_of_bicalutamide

   Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...

7. This Unexpected Pain Is a Common Sign of Prostate Cancer ...

   www.aol.com/unexpected-pain-common-sign-prostate...

   Prostate cancer is one of the most common types of cancer in men, ranking only behind lung cancer in deaths. About 1 in 8 men will be diagnosed with prostate cancer during their lives, according ...